RESPIROLOGY呼吸学
RESPIROLOGY(英文缩写 RESPIROLOGY),ISSN 1323-7799,eISSN 1440-1843,中文译名:呼吸学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 6.175 | Q1 |
| 2022 | 6.900 | Q1 |
| 2023 | 6.600 | Q1 |
| 2024 | 6.300 | Q1 |
| 2025 | 7.200 | Q1 |
RESPIROLOGY 最新收录文献
-
1. Life After Non-COVID-19 Respiratory Viral Illnesses.
1. 非COVID-19呼吸道病毒感染后的生活PMID:日期:2026-10-01该文献暂无摘要。
-
2. Towards a Tobacco Endgame in Hong Kong: A Pragmatic Model for the Asia-Pacific.
PMID:日期:2026-10-01该文献暂无摘要。
-
3. Are We Closer to Predicting Radiological Progression Among ILD Patients?
3. 我们是否更接近于预测ILD患者的影像学进展？PMID:日期:2026-09-29该文献暂无摘要。
-
4. Pulmonary Alveolar Proteinosis: Is the Focus in Treatment Shifted From 'Physical' to 'Pharmacological'?
4. 肺泡蛋白沉积症：治疗焦点是否已从“物理”转向“药理”？PMID:日期:2026-09-24该文献暂无摘要。
-
5. Collaboration for Respiratory Health in Asia-Pacific: Renewing a Key Partnership.
PMID:日期:2026-09-20该文献暂无摘要。
-
6. Impact of Cardiovascular Comorbidities on Clinical Outcomes Across the Asthma Spectrum.
PMID:日期:2026-09-20Cardiovascular disease (CVD) is a prevalent comorbidity in asthma, yet its impact on clinical outcomes across disease states remains poorly characterised. We analysed data from two independent prospective cohorts. Cohort I comprised 1058 stable asthma patients (CVD: n = 107; non-CVD: n = 951) followed for 12 months to assess asthma exacerbations. Cohort II comprised 825 patients hospitalised for an acute exacerbation (CVD: n = 233; non-CVD: n = 592). Missing data were handled by multiple imputation, and the CVD and non-CVD groups were balanced using propensity score overlap weighting. Associations were estimated using negative binomial, gamma, and logistic regression. Mediation and dominance analyses were performed as exploratory analyses. Patients with CVD exhibited greater airflow obstruction and a predominantly non-T2 inflammatory profile characterised by increased neutrophilic inflammation. White blood cells, neutrophils, and monocytes partially mediated the association between CVD and lower FEV/FVC ratio, while monocytes additionally mediated the association between CVD and severe exacerbations. In Cohort I, CVD was independently associated with severe exacerbations (adjusted IRR = 1.96, 95% CI (1.12, 3.44)), hospitalisations, and emergency visits. In Cohort II, CVD was associated with longer hospital stay (adjusted IRR = 1.14, 95% CI (1.01, 1.30)) and higher direct costs, with stroke and coronary heart disease as leading contributors to prolonged stay. CVD is independently associated with worse clinical outcomes across the asthma disease spectrum. These findings support recognition of CVD as an important treatable trait in asthma and highlight the need for integrated cardiopulmonary management.
-
8. Safety and Efficacy of Direct Cryobiopsy Specimen Retrieval Through the 3.0-mm Working Channel of a Therapeutic Bronchoscope Using a 1.1-mm Cryoprobe: A Multicentre Prospective Observational Study.
PMID:日期:2026-09-16Cryobiopsy using a 1.1-mm cryoprobe through a therapeutic bronchoscope with a 3.0-mm working channel permits en bloc retrieval of the cryoprobe and guide sheath while the bronchoscope remains wedged in the target bronchus, potentially facilitating immediate haemostatic control. This study investigated the safety and efficacy of this technique. This prospective observational study enrolled patients with peripheral pulmonary lesions suspected of lung cancer who underwent forceps biopsy (FB), followed by cryobiopsy using a 1.1-mm cryoprobe through a therapeutic bronchoscope with a 3.0-mm working channel. The primary endpoint was procedural safety, as assessed by bleeding grade. The secondary endpoints included procedure-related complications, diagnostic yield, specimen size, procedural success rate, and biomarker analysis success rate. Of 100 enrolled patients, 96 were included in the analysis, and 84 underwent cryobiopsy. Bleeding severity was Grade 0 in 35.4% (34 of 96), Grade 1 in 41.7% (40 of 96), Grade 2 in 8.3% (8 of 96), and Grade 3 in 2.1% (2 of 96) of patients. Diagnostic yields were 77.0% (74 of 96) for FB and 79.1% (76 of 96) for cryobiopsy, with an overall yield of 87.5% (84 of 96). Cryobiopsy provided the sole diagnosis in 10 patients and yielded significantly larger specimens than FB (7.06 vs. 2.46 mm; p < 0.001). The success rate of multiplex genetic testing was 95.8% for cryobiopsy (23 of 24). Direct retrieval of cryobiopsy specimens through the working channel of a therapeutic bronchoscope is safe and feasible, yielding larger specimens with complementary diagnostic value.
-
10. Targeting EGFR-Mutant Non-Small Cell Lung Cancer in Asia: An Update on Monotherapy and Combination Therapy With EGFR Inhibitors.
PMID:日期:2026-09-16EGFR-mutant lung cancer represents a major subtype of non-small cell lung cancer in Asia, with particularly high prevalence in never-smokers, women, and patients with adenocarcinoma histology. Although this clinicopathologic enrichment has been recognized for more than two decades, the mechanisms underlying the excess frequency of EGFR-mutant disease in Asian populations remain only partially understood. Accumulating evidence suggests a multifactorial basis involving host genetic susceptibility and diversity, endogenous mutational processes and exogenous exposures such as ambient particulate matter. In particular, recent genomic and experimental studies support a tumour-promotion framework in which inflammatory microenvironmental cues may facilitate the outgrowth of pre-existing oncogenic clones, while mutational signatures provide genomic footprints of these processes. In parallel, the treatment landscape for EGFR-mutant non-small cell lung cancer has evolved substantially with successive generations of EGFR tyrosine kinase inhibitors (EGFR-TKIs), leading to marked improvements in survival. However, acquired resistance remains inevitable in most patients with advanced disease and is driven by both genetic and non-genetic mechanisms, including secondary EGFR alterations, bypass pathway activation, TP53-associated genomic instability, adaptive mutagenesis, and drug-tolerant persister states. These insights have provided a strong rationale for combination strategies beyond EGFR-TKI monotherapy. In this review, we summarize current understanding of the epidemiology and biological basis of EGFR-mutant lung cancer in Asia and discuss the preclinical rationale and emerging clinical evidence supporting combination approaches with chemotherapy, anti-angiogenic agents, and EGFR/MET-directed therapies.